Physicians Begin Testing First Human Papillomavirus Vaccine

February 03, 1997

Physicians at the University of Rochester Medical Center are beginning the world's first test in humans of a potential vaccine to protect against human papillomavirus (HPV) infections, one of the most common sexually transmitted diseases. Physicians estimate that 20 to 40 million people in the U.S. alone carry HPV, which causes warts of the genital tract and causes nearly all cases of cervical cancer in women.

The vaccine, developed by University researchers working together with scientists at MedImmune, Inc. of Gaithersburg, Md., will be tested at the University during the next year in healthy volunteers who have no symptoms of HPV infection. The study will be led by Richard Reichman, M.D., director of the Infectious Diseases Unit of the Department of Medicine and professor of medicine and microbiology and immunology. The Food and Drug Administration cleared the study in December.

Several scientists and physicians have contributed to the development of the vaccine. In addition to Reichman, Rochester members of the team include Robert C. Rose, Ph.D., senior instructor in medicine, and William Bonnez, M.D., associate professor of medicine. The three are members of the Infectious Diseases Unit of the Department of Medicine. Also collaborating with MedImmune on the technology are scientists from Georgetown University, the German Cancer Institute, and the National Institutes of Health.

"HPV infection is very, very common, affecting up to 40 percent of people in certain age groups, such as sexually active men and women under the age of 30," says Reichman. "This vaccine approach has proven safe and effective at preventing similar infections in animals, and we're hopeful that comparable results will be obtained in humans as well."

The year-long study is to verify the safety of the compound and to check whether it causes the desired immune response -- the formation of antibodies to HPV.

The key to the vaccine is a genetic technology designed to trigger an immune response. The Rochester team cloned the gene that codes for the virus's protein envelope or "capsid," then used a cell line derived from insects to make a large amount of virus-like particles. The particles are not infectious, and they share few traits with real HPV except for their shape. That could be enough for a vaccine, though, since it's the shape of a particle that often marks it as an invader and spurs the body to mount an immune attack.

One of the reasons HPV has eluded vaccine makers is that the virus, unlike herpes or the flu or even HIV, won't grow in a laboratory dish, making it extremely difficult to study. The Rochester team was one of few to find a way to use mice to grow large amounts of the virus for study.

HPV actually stands for a family of more than 75 closely related viruses. A few are harmless and cause such nuisances as warts on the hands or plantar's warts on the feet, but as many as 30 infect the genital tract, causing warts that are difficult to treat and that recur often. Of those 30, a handful cause nearly all of the 15,000 cases of cervical cancer that occur in women in the U.S. alone every year. About 5,000 women in the U.S. die of the disease every year; in some areas of the world, HPV-induced cervical cancer is the leading cause of death by cancer in women.

Since there are so many different HPV types, any vaccine will have to protect against several of them, much like polio and pneumonia vaccines do. While the trial vaccine is targeted against only HPV type 11, researchers have already produced virus-like particles against several other types. Those could be incorporated as part of a broader vaccine.

If the current study shows that the vaccine is safe and able to provoke an immune response, the next step will probably be an even larger study, says Reichman. It usually takes at least four years to completely evaluate a vaccine.

The University has filed for a patent on the HPV vaccine technology and has licensed the rights to MedImmune, a biotechnology company that develops and markets products for the prevention and treatment of infectious diseases and for use in transplantation medicine.
-end-


University of Rochester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.